Merck KGaA

MRK

Equity

ISIN DE0006599905 / Valor 412799

Xetra (2024-09-18)

EUR 166.00-0.39%

Merck KGaA
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Merck KGaA is a global science and technology company headquartered in Darmstadt, Germany, with a history spanning more than 350 years. The company operates across three business sectors: Life Science, Healthcare, and Electronics. In the Life Science sector, Merck provides a wide range of laboratory tools, services, and solutions that support scientific research and bioprocessing for drug manufacturing. The Healthcare division focuses on developing and delivering treatments for serious diseases, including oncology, neurology, immunology, fertility, and endocrinology. Meanwhile, the Electronics sector offers advanced materials, technologies, and solutions for the semiconductor, display, and surface solutions industries. With approximately 63,000 employees in 65 countries, Merck KGaA is dedicated to leveraging science and technology to improve access to health, empower scientific research, and drive human progress through innovation in its diverse fields of operation.

Summarized from source with an LLMView SourceSector: Healthcare

Net Sales

In Q2 2024, Merck KGaA reported net sales of €5,352 million, reflecting a slight increase of 0.9% compared to €5,302 million in Q2 2023. However, for the first half of 2024, net sales decreased by 1.2% to €10,472 million from €10,595 million in the same period of the previous year.

Operating Result (EBIT)

Merck KGaA's operating result (EBIT) for Q2 2024 was €792 million, a significant decline of 18.3% from €969 million in Q2 2023. The EBIT margin also decreased to 14.8% from 18.3% in the same quarter last year. For the first half of 2024, EBIT fell by 14.0% to €1,724 million from €2,004 million in the first half of 2023.

EBITDA

EBITDA for Merck KGaA in Q2 2024 was €1,472 million, showing a modest increase of 1.4% from €1,452 million in Q2 2023. The EBITDA margin remained relatively stable at 27.5% compared to 27.4% in the same quarter last year. For the first half of 2024, EBITDA decreased by 2.9% to €2,857 million from €2,942 million in the first half of 2023.

Profit After Income Tax

Merck KGaA's profit after income tax for Q2 2024 was €605 million, a decrease of 14.3% from €706 million in Q2 2023. For the first half of 2024, profit after income tax declined by 13.3% to €1,305 million from €1,506 million in the same period of the previous year.

Operating Cash Flow

In Q2 2024, Merck KGaA reported an operating cash flow of €861 million, a substantial increase of 38.4% compared to €622 million in Q2 2023. For the first half of 2024, operating cash flow rose by 28.6% to €1,896 million from €1,475 million in the first half of 2023.

Summarized from source with an LLMView Source

Key figures

3.23%1Y

-15.5%3Y

67.5%5Y

Performance

27.8%1Y

28.7%3Y

28.0%5Y

Volatility